CannabisPhase 4NCT03555968
Effects of THC and Alcohol on Driving Performance
A Phase 4 study testing THC 0, THC 5 and THC 10 in people with Cannabis and Alcohol Drinking, run by Lakehead University.
Trial summary
Low blood concentrations of THC and alcohol appear to have a minimal effect on driving performance.However, there is a gap in the literature about the combined effects of THC and alcohol. There is little empirical evidence to determine whether the combination of THC and alcohol could be additive or multiplicative. Read more about this study
- Who is it for?
- Ages 19 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Cannabis, Alcohol Drinking, Accident, Traffic
- What is being tested?
- THC 0, THC 5 and THC 10
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Jul 2021to Dec 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI >18 and <30
- valid G2 or G Ontario driver's license
- live on-campus or within 15 minutes drive of campus
- speak fluent English
Who cannot join
- history of cardiovascular or psychiatric disorders
- current use of psychoactive medication
- current drug or alcohol abuse problem
- positive drug screen
- BAC level > .000%
About this study
Official title: Determining the Combined Effects of THC and Alcohol on Driving Performance
Low blood concentrations of THC and alcohol appear to have a minimal effect on driving performance.However, there is a gap in the literature about the combined effects of THC and alcohol. There is little empirical evidence to determine whether the combination of THC and alcohol could be additive or multiplicative. This issue is particularly important when dealing with concentrations that are just below legal thresholds - it is important to identify if someone who may have consumed cannabis and alcohol, in quantities that do not exceed legal thresholds, may nonetheless be impaired to drive. Answering this question requires more research on the combined effects of THC and alcohol under tightly controlled experimental conditions. Hence, the purpose of this study is to determine the additive (or multiplicative) effect of standardized low doses of cannabis, in combination with low-doses of alcohol, on a number of outcome measures related to driving. The investigators will focus specifically on the effect of low blood concentrations of THC (0, 125, and 250 µg/kg) alone and in combination with low blood concentrations of alcohol (BAC 0%, .025%, and .049%). They shall determine the combined effect of THC and alcohol on physiological, cognitive, subjective measures of impairment, and simulated driving. This study will focus on younger adults because they have higher impaired driving rates than other age groups. As a secondary aim of the study, the investigators will examine whether previous driving and drug use history are correlated with driving decisions during the simulated drive and subjective measures. This study will contribute to the evidence base informing legislation, policy making, and law enforcement. This study is particularly timely given upcoming changes in legislation about cannabis, and because the combination of THC and alcohol, even below legal thresholds, may lead to impaired driving and crashes.
- Conditions
- Cannabis, Alcohol Drinking, Accident, Traffic
- Being tested
- THC 0, THC 5, THC 10, BAC 0, BAC .025
- Keywords
- THC, Alcohol, Driving, Dronabinol
- Medical subject headings
- Marijuana Abuse, Alcohol Drinking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
THC 0Drug
Also called Tetrahydrocannabinol, Dronabinol, Cannabis
THC dose = 0mg
THC 5Drug
Also called Tetrahydrocannabinol, Dronabinol, Cannabis
THC dose = 5mg
THC 10Drug
Also called Tetrahydrocannabinol, Dronabinol, Cannabis
THC dose = 10mg
BAC 0Other
Blood alcohol concentration = .000%
BAC .025Other
Blood alcohol concentration = .025%
BAC .049Other
Blood alcohol concentration = .049%
| Study group | Role | What they receive |
|---|---|---|
| THC 0 + BAC 0 | Placebo comparator | Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%. Receives: Drug: THC 0; Other: BAC 0 |
| THC 5 + BAC 0 | Experimental | Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%. Receives: Drug: THC 5; Other: BAC 0 |
| THC 10 + BAC 0 | Experimental | Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%. Receives: Drug: THC 10; Other: BAC 0 |
| THC 5 + BAC .025 | Experimental | Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%. Receives: Drug: THC 5; Other: BAC .025 |
| THC 10 + BAC .025 | Experimental | Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%. Receives: Drug: THC 5; Other: BAC .025 |
| THC 0 + BAC .049 | Experimental | Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%. Receives: Drug: THC 0; Drug: THC 10; Other: BAC .025; Other: BAC .049 |
| THC 5 + BAC .049 | Experimental | Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%. Receives: Drug: THC 5; Other: BAC .049 |
| THC 10 + BAC .049 | Experimental | Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%. Receives: Drug: THC 5; Other: BAC .049 |
| THC 0 + BAC .025 | Experimental | Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%. Receives: Drug: THC 0; Drug: THC 10; Other: BAC .025; Other: BAC .049 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Demerit Points on Simulated Road Test
Demerit points incurred for driving errors during a simulated a G2 exit exam (the final step in Ontario's graduated licensing framework) on a STISIM Drive 3-screen driving simulator; demerit points will be assigned in real-time by a member of the research team based on the Ontario Ministry of Transportation scoring scheme
Measured: @2.5 hours
Secondary outcomes (9)
Standard Deviation of Lane Position in Meters (STISIM Drive-Recorded Variable)
Recorded by the STISIM simulator during the simulation
Measured: @2.5 hours
Mean and Standard Deviation of Velocity in Meters/Second (STISIM Drive-Recorded Variable)
Recorded by the STISIM simulator during the simulation
Measured: @2.5 hours
Mean and Standard Deviation of Acceleration in Meters/Second (STISIM Drive-Recorded Variable)
Recorded by the STISIM simulator during the simulation
Measured: @2.5 hours
Blood Pressure (Systolic/Diastolic mmHg)
Systolic \& diastolic blood pressure via automated blood pressure cuff
Measured: @25 minutes and 2 hours
Heart Rate (BPM) & Heart Rate Variability via ECG
Continuous heart rate in beats per minute via 3-lead electrocardiography recording; will allow for calculation of heart rate variability)
Measured: Hour 0-3.5
Electrical Brain Activity via EEG
Continuous brain activity via electroencephalography recording
Measured: Hour 0-3.5
Median Response Time and Efficiency in Alerting, Orienting & Executive Attention as Measured by the Attention Network Test (in milliseconds)
A computerized test to measure participants' performance in three separate components of attention: alerting, orienting, and executive attention
Measured: @25 minutes and 2 hours
Perceptual Motor Speed & Efficiency as Measured by Time (in seconds) to Complete Trail Making Tests A&B
A pen and paper test to measure perceptual motor speed and efficiency
Measured: @25 minutes and 2 hours
Visual Analogue Scale of Perceived Effects
Ratings of participants' current perceptions of mood and bodily sensations (22 items including anxiety, alertness, dizziness, dry mouth) driving (3 items related to current willingness to drive), and subjective impairment (at time 2 only; 6 items related to strength of effects, perceived performance on tests); all items measures from not at all>extremely or absent>severe on a 100 mm line
Measured: @25 minutes and 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2018
- Study startJul 2021 (estimated)
- Primary completionDec 2021 (estimated)
- Study completionDec 2021 (estimated)
Why it stopped: Logistical issues
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CannabisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lakehead University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michel Bédard, PhD, Principal investigator, Lakehead University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03555968
- Sponsor's protocol ID
- 2018502
- Status last verified
- Apr 2022
- First submitted
- 18 May 2018
- Last updated
- 25 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determining the Combined Effects of THC and Alcohol on Driving Performance
- ClinicalTrials.gov ID
- NCT03555968
- Acronym / sponsor ID
- 2018502
- Conditions
- Cannabis, Alcohol Drinking, Accident, Traffic
- Keywords
- THC, Alcohol, Driving, Dronabinol
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Logistical issues
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Lakehead UniversityUniversity, hospital or other
- Study start
- Jul 2021 (estimated)
- Primary completion
- Dec 2021 (estimated)
- Study completion
- Dec 2021 (estimated)
- First posted
- 14 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Low blood concentrations of THC and alcohol appear to have a minimal effect on driving performance.However, there is a gap in the literature about the combined effects of THC and alcohol. There is little empirical evidence to determine whether the combination of THC and alcohol could be additive or multiplicative. This issue is particularly important when dealing with concentrations that are just below legal thresholds - it is important to identify if someone who may have consumed cannabis and alcohol, in quantities that do not exceed legal thresholds, may nonetheless be impaired to drive. Answering this question requires more research on the combined effects of THC and alcohol under tightly controlled experimental conditions. Hence, the purpose of this study is to determine the additive (or multiplicative) effect of standardized low doses of cannabis, in combination with low-doses of alcohol, on a number of outcome measures related to driving. The investigators will focus specifically on the effect of low blood concentrations of THC (0, 125, and 250 µg/kg) alone and in combination with low blood concentrations of alcohol (BAC 0%, .025%, and .049%). They shall determine the combined effect of THC and alcohol on physiological, cognitive, subjective measures of impairment, and simulated driving. This study will focus on younger adults because they have higher impaired driving rates than other age groups. As a secondary aim of the study, the investigators will examine whether previous driving and drug use history are correlated with driving decisions during the simulated drive and subjective measures. This study will contribute to the evidence base informing legislation, policy making, and law enforcement. This study is particularly timely given upcoming changes in legislation about cannabis, and because the combination of THC and alcohol, even below legal thresholds, may lead to impaired driving and crashes.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 9
| Arm | Type | Receives |
|---|---|---|
| THC 0 + BAC 0 | Placebo comparator | Drug: THC 0, Other: BAC 0Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%. |
| THC 5 + BAC 0 | Experimental | Drug: THC 5, Other: BAC 0Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%. |
| THC 10 + BAC 0 | Experimental | Drug: THC 10, Other: BAC 0Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%. |
| THC 5 + BAC .025 | Experimental | Drug: THC 5, Other: BAC .025Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%. |
| THC 10 + BAC .025 | Experimental | Drug: THC 5, Other: BAC .025Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%. |
| THC 0 + BAC .049 | Experimental | Drug: THC 0, Drug: THC 10, Other: BAC .025, Other: BAC .049Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%. |
| THC 5 + BAC .049 | Experimental | Drug: THC 5, Other: BAC .049Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%. |
| THC 10 + BAC .049 | Experimental | Drug: THC 5, Other: BAC .049Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%. |
| THC 0 + BAC .025 | Experimental | Drug: THC 0, Drug: THC 10, Other: BAC .025, Other: BAC .049Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%. |
Who may qualify
- Ages
- 19 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- BMI >18 and <30
- valid G2 or G Ontario driver's license
- live on-campus or within 15 minutes drive of campus
- speak fluent English
Key exclusion criteria (5 listed)
- history of cardiovascular or psychiatric disorders
- current use of psychoactive medication
- current drug or alcohol abuse problem
- positive drug screen
- BAC level > .000%
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| THC 0Also: Tetrahydrocannabinol, Dronabinol, CannabisTHC dose = 0mg | Drug | THC 0 + BAC .025, THC 0 + BAC .049, THC 0 + BAC 0 |
| THC 5Also: Tetrahydrocannabinol, Dronabinol, CannabisTHC dose = 5mg | Drug | THC 10 + BAC .025, THC 10 + BAC .049, THC 5 + BAC .025, THC 5 + BAC .049, THC 5 + BAC 0 |
| THC 10Also: Tetrahydrocannabinol, Dronabinol, CannabisTHC dose = 10mg | Drug | THC 0 + BAC .025, THC 0 + BAC .049, THC 10 + BAC 0 |
| BAC 0Blood alcohol concentration = .000% | Other | THC 0 + BAC 0, THC 10 + BAC 0, THC 5 + BAC 0 |
| BAC .025Blood alcohol concentration = .025% | Other | THC 0 + BAC .025, THC 0 + BAC .049, THC 10 + BAC .025, THC 5 + BAC .025 |
| BAC .049Blood alcohol concentration = .049% | Other | THC 0 + BAC .025, THC 0 + BAC .049, THC 10 + BAC .049, THC 5 + BAC .049 |
Primary outcome
Demerit Points on Simulated Road Test
Time frame: @2.5 hours
Demerit points incurred for driving errors during a simulated a G2 exit exam (the final step in Ontario's graduated licensing framework) on a STISIM Drive 3-screen driving simulator; demerit points will be assigned in real-time by a member of the research team based on the Ontario Ministry of Transportation scoring scheme
9 secondary outcomes
Standard Deviation of Lane Position in Meters (STISIM Drive-Recorded Variable)
Time frame: @2.5 hours
Mean and Standard Deviation of Velocity in Meters/Second (STISIM Drive-Recorded Variable)
Time frame: @2.5 hours
Mean and Standard Deviation of Acceleration in Meters/Second (STISIM Drive-Recorded Variable)
Time frame: @2.5 hours
Blood Pressure (Systolic/Diastolic mmHg)
Time frame: @25 minutes and 2 hours
Heart Rate (BPM) & Heart Rate Variability via ECG
Time frame: Hour 0-3.5
Electrical Brain Activity via EEG
Time frame: Hour 0-3.5
Median Response Time and Efficiency in Alerting, Orienting & Executive Attention as Measured by the Attention Network Test (in milliseconds)
Time frame: @25 minutes and 2 hours
Perceptual Motor Speed & Efficiency as Measured by Time (in seconds) to Complete Trail Making Tests A&B
Time frame: @25 minutes and 2 hours
Visual Analogue Scale of Perceived Effects
Time frame: @25 minutes and 2 hours
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Apr 2022.
- Individual participant dataSharing planned: No
Related trials for Cannabis
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
RecruitingPhase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer Disease, Agitation
Not yet recruitingPhase 1
PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis
Cigarette Smoking-Related Carcinoma
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michel Bédard, PhD principal investigator
Lakehead University
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing THC 0, THC 5 and THC 10 in people with Cannabis and Alcohol Drinking, run by Lakehead University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 25 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Demerit Points on Simulated Road Test (time frame: @2.5 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2022.